TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Our real-world findings, when viewed in conjunction with those from clinical studies that have reported ORRs of 53–60% in patients with cHL and 59–88% in patients with CD30-expressing PTCL retreated with BV, suggest that BV retreatment may be a viable option for some patients, including those intolerant to aggressive therapy.